Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years old
• People whose overall health and ability to carry out daily activities falls within a certain range, as measured by a standard medical scoring system called the ECOG scale (scores 0–2) (confirm with trial site)
• People with a life expectancy of at least 3 months
• People with a confirmed diagnosis of multiple myeloma
• People whose multiple myeloma is measurable through standard tests at the time of screening
• People whose recent blood and other lab results meet the levels required by the trial protocol, tested within 7 days before the first dose
• People whose side effects from any previous cancer treatment have mostly or fully resolved before starting the trial
• Female participants who could become pregnant, and male participants whose partners could become pregnant, must use at least one accepted form of contraception throughout the treatment period and for at least 7 months after the last dose
• Male participants must not donate sperm from the time they sign the consent form until at least 7 months after the last dose

Who may not be able to join:

• People whose multiple myeloma did not respond to their very first treatment (primary refractory multiple myeloma)
• People who have soft tissue plasma cell tumours outside of the bone at the time of screening
• People with known or strongly suspected involvement of multiple myeloma in the brain or spinal fluid
• People with a history of moderate to severe nerve damage in the hands or feet (Grade 2 or higher peripheral neuropathy)
• People who have had an active infection requiring treatment with systemic medicines within the 2 weeks before the first dose
• People whose high blood pressure has not been well controlled with standard medication in the 2 weeks before the first dose
• People with a history of a severe high blood pressure crisis or high blood pressure affecting the brain
• People with poorly controlled diabetes
• People who have had a serious heart or stroke-related event within the 6 months before the first dose
• People with an active hepatitis B or hepatitis C infection
• People with a known history of active tuberculosis or active syphilis
• People with a known allergy to any ingredient in the study treatment
• People who have had a severe (Grade 3–4) or life-threatening allergic reaction to any biological medicine
• People who have previously received treatment targeting a protein called LILRB4, or who had a severe reaction to a prior treatment containing a substance called MMAE
• People who received certain types of cancer treatments too recently before the first dose, including biological therapies within 28 days, chemotherapy or small molecule therapies within 14 days, or certain approved herbal medicines with cancer indications within 7 days
• People who need ongoing high-dose steroid medicines or other immune-suppressing medicines within 14 days before or during the trial (doses above the equivalent of 10 mg prednisone per day)
• People who received a live or live-attenuated vaccine within 28 days before the first dose
• People who received other vaccines (such as inactivated COVID-19 vaccines) within 14 days before the first dose
• People who had to permanently stop a previous immunotherapy due to immune-related side effects
• People with a current or previous history of certain lung-scarring or lung-inflammation conditions, including idiopathic pulmonary fibrosis or idiopathic pneumonia
• People with a current active lung disease, including interstitial lung disease or pneumonia
• People diagnosed with any other cancer within the 5 years before the first dose
• People with a documented history of a neurological or psychiatric condition
• People whom the trial doctor considers unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.